CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 192 enrolled
Drug / intervention
Methotrexate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03739853
NCT03739853Phase 4Completed

Clinical Effectiveness of Standard Step up Care (Methotrexate) Compared to Early Combination DMARD Therapy With Standard Step up Care Compared to Early Use of TNF Inhibitors With Standard Step up Care for the Treatment of Moderate to Severe Psoriatic Arthritis: a 3-arm Parallel Group Randomised Controlled Trial.

University of Oxford·interventional·Posted Nov 14, 2018·Updated Nov 26, 2025

In Brief

A Phase 4 clinical trial evaluating Methotrexate, Sulfasalazine, and 2 other interventions for Psoriatic Arthritis. Completed, enrolled 192 participants across 1 site.

Detailed Summary

SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA. Arm 1 will receive standard step up therapy in the cohort and act as the control group. Arm 2 will receive early combination conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). Arm 3 will receive early tumour necrosis factor (TNF) inhibitor therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedNov 14, 2018
Enrollment StartMay 14, 2019
Primary CompletionOct 31, 2024
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 7.6 years ago

Interventions

Methotrexatedrug

Used in all three arms of study

Sulfasalazinedrug

Used in arm 2 of study

Leflunomidedrug

Used in arm 2 of study

Adalimumabdrug

Used in arm 3 of the study only